Clinical Pharmacokinetics of Enalapril and Enalaprilat in Pediatric Patients-A Systematic Review
Publication year
2021Source
Frontiers in Pediatrics, 9, (2021), article 611322ISSN
Publication type
Article / Letter to editor
Display more detailsDisplay less details
Organization
Pharmacology-Toxicology
Intensive Care
Journal title
Frontiers in Pediatrics
Volume
vol. 9
Subject
Radboudumc 11: Renal disorders RIHS: Radboud Institute for Health Sciences; Pharmacology-Toxicology - Radboud University Medical CenterAbstract
Purpose: Enalapril has an established safety and efficacy in adults and is used in hypertension, heart failure, and renal failure. In pediatric patients, enalapril is labeled for children with hypertension and used off label in children with heart failure. The systematic literature search aims to assess the current knowledge about enalapril and its active metabolite enalaprilat pharmacokinetics in children as a basis for dose delineation for pediatric patients with heart failure. Methods: A systematic literature review was performed in the PubMed database using relevant keywords. Dose normalization of relevant pharmacokinetic parameters of the identified studies was done for comparison between different diseases and pediatric age groups. Results: The literature search has resulted in three pediatric pharmacokinetic studies of enalapril out of which Wells et al. reported about children with hypertension and Nakamura et al., and Llyod et al. presented data for pediatric heart failure patients. The area under the curve values of enalaprilat in hypertensive pediatric patients increased with respect to the age groups and showed maturation of body functions with increasing age. Dose normalized comparison with the heart failure studies revealed that although the pediatric heart failure patients of > 20 days of age showed the area under the curve a similar to that of hypertensive patients, two pediatric patients of very early age (<20 days) were presented with 5-6-fold higher area under the curve values. Conclusion: Data related to the pharmacokinetics of enalapril and enalaprilat in hypertensive patients and few data for young heart failure children are available. Comparison of dose normalized exposition of the active metabolite enalaprilat indicated similarities between heart failure and hypertensive patients and a potentially high exposition of premature patients but substantially more pharmacokinetic studies are required to have reliable and robust enalapril as well as enalaprilat exposures especially in pediatric patients with heart failure as a basis for any dose delineation.
This item appears in the following Collection(s)
- Academic publications [246936]
- Electronic publications [134293]
- Faculty of Medical Sciences [93487]
- Open Access publications [107816]
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.